Last reviewed · How we verify
Ventolin® MDI
Ventolin MDI delivers albuterol (salbutamol), a beta-2 adrenergic agonist that relaxes airway smooth muscle to rapidly relieve bronchospasm and improve airflow.
Ventolin MDI delivers albuterol (salbutamol), a beta-2 adrenergic agonist that relaxes airway smooth muscle to rapidly relieve bronchospasm and improve airflow. Used for Acute asthma exacerbation and bronchospasm relief, Maintenance therapy for asthma and chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Ventolin® MDI |
|---|---|
| Sponsor | Taiwan Otsuka Pharm. Co., Ltd |
| Drug class | Beta-2 adrenergic agonist (short-acting bronchodilator) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Albuterol binds to beta-2 adrenergic receptors on bronchial smooth muscle cells, activating intracellular signaling that increases cAMP levels and causes muscle relaxation. This bronchodilation rapidly opens constricted airways, providing quick relief of acute asthma symptoms and shortness of breath. The metered-dose inhaler (MDI) formulation delivers the drug directly to the lungs for rapid local action.
Approved indications
- Acute asthma exacerbation and bronchospasm relief
- Maintenance therapy for asthma and chronic obstructive pulmonary disease (COPD)
Common side effects
- Tremor
- Headache
- Nervousness or anxiety
- Palpitations
- Muscle cramps
- Tachycardia
Key clinical trials
- A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma (PHASE2)
- Assessment of Emergency Spacers Versus Traditional Spacers for Delivery of Aerosolized Drugs (PHASE4)
- An Exploratory Study to Characterise Changes in Airway Inflammation, Symptoms, Lung Function and Reliever Use in Adult Asthma Patients (PHASE4)
- Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087) (PHASE3)
- Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients. (PHASE4)
- Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing (PHASE4)
- To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years. (PHASE1)
- Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ventolin® MDI CI brief — competitive landscape report
- Ventolin® MDI updates RSS · CI watch RSS
- Taiwan Otsuka Pharm. Co., Ltd portfolio CI